Today in Peak History (August 1-10)
Release time:
2020-08-14
peak (# March - 10 )
1981 8 , Jinhua cement factory tried out the economic responsibility system and distributed bonuses by the over-quota piece-rate method, which was calculated by the methods of setting posts, posts, responsibilities and awards.
1994 , Jianfeng Group was identified as the first batch of typical enterprises in the country to change their operating mechanism.
◆ 1995 8 August, Jianfeng Group was named the first national excellent enterprise in building materials industry.
◆ 2002 8 , the national new drug "Yufeng Ningxin Dropping Pills" was approved for listing. This variety is the first to be listed in China, filling the gap of this dosage form in the province.
◆ 2007 8 February, the "peak" trademark was judicially recognized as a well-known trademark in China.
◆ 2009 8 September 3 , Jianfeng International Trading Co., Ltd. was approved as the designated delivery warehouse of Dalian Commodity Exchange PVC (polyvinyl chloride).
2009 8 8 , daye peak cement company's waste heat power generation project was successfully connected to the grid.
◆ 2011 8 September 4 , Chairman Jiang Xiaomeng of the Group Company was awarded the honorary title of "Outstanding Entrepreneur of Zhejiang Province" in the 10th session.
◆ 2012 8 3 , Yunnan Jianfeng cement production line project was officially ignited and put into trial production on 18 .
◆ In 2013 8 , the workshop of daye peak cement company won the honorary title of "national advanced collective in building materials industry.
◆ 2013 8 , Jianfeng Group was shortlisted for 2013 China Building Materials Enterprise 500 , and Daye Jianfeng Cement Company was shortlisted for 2013 China Building Materials Enterprise 100 .
◆ 2014 # In August , Jinxi Project of Jianfeng Pharmaceutical Company was selected into 100 demonstration projects of "machine substitution" in Zhejiang Province in 2014 .
◆ 2014 8 9 , Jianfeng Health Technology Company Health Experience Hall opened.
◆ 2015 August# December 9, Jinhua Pharmaceutical Company successfully auctioned an enterprise land through Taobao Judicial Auction Platform. This is the first time Jianfeng Group has purchased land in the form of online auction.
2015 # August 13 June, daye peak cement company passed the secondary safety standardization on-site review. ◆
August March, the group company signed a school-enterprise strategic cooperation agreement with Guangxi medical university. ◆
August , the academician expert workstation of Jianfeng Pharmaceutical Industry was approved by relevant departments of Zhejiang Province and upgraded to the provincial academician expert workstation. ◆
July, the Sino-German joint venture Zhejiang Jinder Baby Drug Co., Ltd., which is controlled by Jianfeng Pharmaceutical, was registered and established (2017 was renamed "Zhejiang Baby Drug Co., Ltd."). On this basis, Spike Pharmaceuticals introduced German technology and products to develop the infant drug market. (Xu Xia finishing)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page